logo
logo

Earli Raises $40 Million Series A Funding Led by Khosla Ventures, With Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital

Jan 12, 2021•over 4 years ago

Amount Raised

$40 Million

Round Type

series a

San Francisco

Description

The biotech industry has been aspiring to develop breakthrough technologies that hold promise for acting early on cancer when the chances of survival are much higher. Bioengineering firm, Earli, which developed in stealth a new platform technology that will allow clinicians to exactly locate early cancers so they can be treated, today announced that it has raised $40 million in Series A funding. The financing was led by Khosla Ventures, along with Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital, and top individuals including Midas List investors Jim Breyer/Breyer Capital and Rahul Mehta, Goldman Sachs’s former CFO and CIO R. Martin Chavez, and biomedical device entrepreneur Shlomo Ben-Haim.

Company Information

Company

Earli

Location

San Francisco, California, United States

About

Earli is a biotechnology company focused on making cancer that is detected early, localizable and therefore treatable, via its novel “Synthetic Biopsies.” By forcing cancer cells to produce synthetic biomarkers that do not belong in the human body, they are made highly detectable and localizable in a PET scanner, so they can be treated at early stages, when survival rates are multiple times higher. Earli uses biology rather than chemistry to force production of the Synthetic Biopsy, allowing for massive signal amplification and targeted treatment. The company is located in South San Francisco’s biotech hub.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People